A Prospective, Non-controlled, Safety Study of Intravenous Iron Isomaltoside 1000 (Monofer) Administered by a High Dosing Regimen in Subjects With Inflammatory Bowel Disease (PROMISE)

Trial Profile

A Prospective, Non-controlled, Safety Study of Intravenous Iron Isomaltoside 1000 (Monofer) Administered by a High Dosing Regimen in Subjects With Inflammatory Bowel Disease (PROMISE)

Completed
Phase of Trial: Phase III

Latest Information Update: 19 May 2015

At a glance

  • Drugs Iron isomaltoside 1000 (Primary)
  • Indications Iron deficiency anaemia
  • Focus Adverse reactions
  • Acronyms PROMISE
  • Sponsors Pharmacosmos
  • Most Recent Events

    • 19 May 2015 According to a Pharmacosmos media release, results from this trial will be presented at the annual European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress.
    • 28 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 20 Aug 2014 Planned End Date changed from 1 Jul 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top